anurajms/meta_analysis huggingface dataset:
MESH terms:
Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis
1. Adrenal Cortex Hormones [therapeutic use]; 2. Adrenergic beta‐2 Receptor Agonists [therapeutic use]; 3. Cholinergic Antagonists [therapeutic use]; 4. DNA‐Binding Proteins; 5. Delayed‐Action Preparations [administration & dosage]; 6. Muscarinic Antagonists [therapeutic use]; 7. Nuclear Proteins; 8. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 9. Randomized Controlled Trials as Topic; 10. Transcription Factors;
MESH terms:
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
1. Administration, Inhalation; 2. Adrenergic beta‐2 Receptor Agonists [administration & dosage, adverse effects]; 3. Androstadienes [administration & dosage, *adverse effects]; 4. Anti‐Inflammatory Agents [administration & dosage, *adverse effects]; 5. Bronchodilator Agents [administration & dosage, *adverse effects]; 6. Budesonide [administration & dosage, *adverse effects]; 7. Drug Therapy, Combination [methods]; 8. Fluticasone; 9. Pneumonia [chemically induced]; 10. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Addition to inhaled corticosteroids of long‐acting beta2‐agonists versus anti‐leukotrienes for chronic asthma
1. Adrenal Cortex Hormones [*therapeutic use]; 2. Adrenergic beta‐2 Receptor Agonists [*therapeutic use]; 3. Anti‐Asthmatic Agents [*therapeutic use]; 4. Asthma [*drug therapy]; 5. Chronic Disease; 6. Drug Therapy, Combination [methods]; 7. Leukotriene Antagonists [*therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Water‐based exercise training for chronic obstructive pulmonary disease
1. Breathing Exercises [methods]; 2. Exercise Therapy [*methods]; 3. Exercise Tolerance; 4. Hydrotherapy [adverse effects, *methods]; 5. Pulmonary Disease, Chronic Obstructive [*rehabilitation]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children
1. Anti‐Asthmatic Agents [*administration & dosage]; 2. Asthma [*drug therapy]; 3. Bronchodilator Agents [*administration & dosage]; 4. Budesonide [*administration & dosage]; 5. Drug Combinations; 6. Ethanolamines [*administration & dosage]; 7. Formoterol Fumarate; 8. Maintenance Chemotherapy [methods]; 9. Nebulizers and Vaporizers; 10. Randomized Controlled Trials as Topic;
MESH terms:
Noninvasive positive‐pressure ventilation as a weaning strategy for intubated adults with respiratory failure
1. Noninvasive Ventilation [*methods]; 2. Pneumonia, Ventilator-Associated [prevention & control]; 3. Positive-Pressure Respiration [*methods, mortality]; 4. Pulmonary Disease, Chronic Obstructive [mortality, *therapy]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Respiratory Insufficiency [mortality, *therapy]; 8. Ventilator Weaning [*methods];
MESH terms:
Antibody induction therapy for lung transplant recipients
1. *Lung Transplantation; 2. Alemtuzumab; 3. Antibodies, Monoclonal [therapeutic use]; 4. Antibodies, Monoclonal, Humanized [therapeutic use]; 5. Antilymphocyte Serum [therapeutic use]; 6. Basiliximab; 7. Daclizumab; 8. Graft Rejection [immunology, *prevention & control]; 9. Immunoglobulin G [therapeutic use]; 10. Immunosuppression Therapy [adverse effects, *methods]; 11. Immunosuppressive Agents [adverse effects, *therapeutic use]; 12. Muromonab‐CD3 [therapeutic use]; 13. Randomized Controlled Trials as Topic; 14. Receptors, Interleukin‐2 [antagonists & inhibitors]; 15. Recombinant Fusion Proteins [therapeutic use]; 16. T‐Lymphocytes [*immunology];
MESH terms:
Smartphone and tablet self management apps for asthma
1. Asthma [*therapy]; 2. *Cell Phone; 3. *Computers, Handheld; 4. *Mobile Applications; 5. Randomized Controlled Trials as Topic; 6. Self Care [instrumentation, *methods];
MESH terms:
Thyrotropin‐releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease
1. Drug Therapy, Combination [methods]; 2. Glucocorticoids [*therapeutic use]; 3. Infant, Premature; 4. *Obstetric Labor, Premature; 5. Randomized Controlled Trials as Topic; 6. Respiratory Distress Syndrome, Newborn [*prevention & control]; 7. Thyrotropin-Releasing Hormone [adverse effects, *therapeutic use];
MESH terms:
Prostaglandins before caesarean section for preventing neonatal respiratory distress
1. *Cesarean Section; 2. Preoperative Care [*methods]; 3. Prostaglandins E [*administration & dosage]; 4. Randomized Controlled Trials as Topic; 5. Respiratory Distress Syndrome, Newborn [*prevention & control];
MESH terms:
Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
1. Adrenergic beta‐2 Receptor Agonists [*therapeutic use]; 2. Bronchodilator Agents [*therapeutic use]; 3. Drug Combinations; 4. Nebulizers and Vaporizers; 5. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Long‐acting beta2‐agonists for chronic obstructive pulmonary disease
1. Administration, Inhalation; 2. Adrenergic beta-2 Receptor Agonists [*administration & dosage]; 3. Drug Administration Schedule; 4. Pulmonary Disease, Chronic Obstructive [drug therapy, mortality]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Beclometasone for chronic obstructive pulmonary disease
1. Adrenergic beta‐2 Receptor Agonists [*therapeutic use]; 2. Beclomethasone [*therapeutic use]; 3. Forced Expiratory Volume [drug effects, physiology]; 4. Glucocorticoids [*therapeutic use]; 5. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Addition of anti‐leukotriene agents to inhaled corticosteroids in children with persistent asthma
1. Acetates [*administration & dosage]; 2. Asthma [*drug therapy]; 3. Cyclopropanes; 4. Drug Therapy, Combination [methods]; 5. Leukotriene Antagonists [*administration & dosage]; 6. Quinolines [*administration & dosage]; 7. Randomized Controlled Trials as Topic; 8. Sulfides;
MESH terms:
Beta2‐agonists for exercise‐induced asthma
1. Administration, Inhalation; 2. Adrenergic beta‐2 Receptor Antagonists [*administration & dosage]; 3. Asthma, Exercise‐Induced [*drug therapy]; 4. Bronchoconstriction; 5. Bronchodilator Agents [*administration & dosage]; 6. Forced Expiratory Volume [drug effects]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Physical training for asthma
1. Asthma [*rehabilitation]; 2. Exercise [*physiology]; 3. Health Status; 4. Physical Fitness [*physiology]; 5. Randomized Controlled Trials as Topic; 6. Respiratory Function Tests;
MESH terms:
Holding chambers (spacers) versus nebulisers for beta‐agonist treatment of acute asthma
1. *Nebulizers and Vaporizers; 2. Acute Disease; 3. Adrenergic beta‐Agonists [*administration & dosage]; 4. Anti‐Asthmatic Agents [*administration & dosage]; 5. Asthma [*drug therapy]; 6. Emergency Service, Hospital [statistics & numerical data]; 7. Equipment Design; 8. Inhalation Spacers [statistics & numerical data]; 9. Length of Stay [statistics & numerical data]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Inspiratory muscle training for asthma
1. Asthma [*rehabilitation]; 2. Breathing Exercises [*methods]; 3. Muscle Strength [physiology]; 4. Randomized Controlled Trials as Topic; 5. Respiratory Muscles [*physiopathology]; 6. Respiratory Therapy [instrumentation, *methods];
MESH terms:
Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
1. Adrenal Cortex Hormones [*administration & dosage, adverse effects]; 2. Adrenergic beta‐2 Receptor Agonists [*administration & dosage, adverse effects]; 3. Albuterol [administration & dosage, adverse effects, analogs & derivatives]; 4. Androstadienes [administration & dosage, adverse effects]; 5. Bronchodilator Agents [administration & dosage, adverse effects]; 6. Budesonide [administration & dosage, adverse effects]; 7. Drug Combinations; 8. Drug Therapy, Combination [adverse effects, methods]; 9. Ethanolamines [administration & dosage, adverse effects]; 10. Fluticasone‐Salmeterol Drug Combination; 11. Formoterol Fumarate; 12. Nebulizers and Vaporizers; 13. Pneumonia [chemically induced]; 14. Pulmonary Disease, Chronic Obstructive [*drug therapy, mortality]; 15. Randomized Controlled Trials as Topic; 16. Steroids [*administration & dosage, adverse effects];
MESH terms:
Combined inhaled anticholinergics and short‐acting beta2‐agonists for initial treatment of acute asthma in children
1. Administration, Inhalation; 2. Adrenergic beta‐2 Receptor Agonists [administration & dosage, *therapeutic use]; 3. Asthma [*drug therapy]; 4. Atropine [administration & dosage, therapeutic use]; 5. Cholinergic Antagonists [administration & dosage, *therapeutic use]; 6. Disease Progression; 7. Drug Therapy, Combination [methods]; 8. Hospitalization [statistics & numerical data]; 9. Ipratropium [administration & dosage, therapeutic use]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome
1. Acute Lung Injury [mortality, *therapy]; 2. Liquid Ventilation [*methods]; 3. Morbidity; 4. Randomized Controlled Trials as Topic; 5. Respiratory Distress Syndrome [mortality, *therapy];
MESH terms:
Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease
1. Administration, Inhalation; 2. Adrenergic beta‐2 Receptor Agonists [*administration & dosage]; 3. Albuterol [administration & dosage, *analogs & derivatives]; 4. Androstadienes [*administration & dosage]; 5. Bronchodilator Agents [*administration & dosage]; 6. Drug Therapy, Combination [methods]; 7. Fluticasone; 8. Patient Dropouts [statistics & numerical data]; 9. Pneumonia [drug therapy]; 10. Pulmonary Disease, Chronic Obstructive [*drug therapy, mortality]; 11. Salmeterol Xinafoate; 12. Scopolamine Derivatives [*administration & dosage]; 13. Tiotropium Bromide;
MESH terms:
Drug therapy for obstructive sleep apnoea in adults
1. Randomized Controlled Trials as Topic; 2. Sleep Apnea, Obstructive [*drug therapy];
MESH terms:
Physician advice for smoking cessation
1. *Patient Education as Topic; 2. *Physician's Role; 3. *Smoking Cessation; 4. *Smoking Prevention; 5. Practice Patterns, Physicians'; 6. Randomized Controlled Trials as Topic; 7. Smoking [mortality]; 8. Treatment Outcome;
MESH terms:
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children
1. Administration, Inhalation; 2. Adrenal Cortex Hormones [*administration & dosage]; 3. Anti‐Asthmatic Agents [*administration & dosage]; 4. Asthma [*drug therapy]; 5. Bronchodilator Agents [administration & dosage]; 6. Budesonide [*administration & dosage]; 7. Chronic Disease; 8. Drug Combinations; 9. Ethanolamines [*administration & dosage]; 10. Formoterol Fumarate; 11. Terbutaline [administration & dosage];
MESH terms:
Swimming training for asthma in children and adolescents aged 18 years and under
1. Asthma [physiopathology, *rehabilitation]; 2. Oxygen Consumption [physiology]; 3. Randomized Controlled Trials as Topic; 4. Respiratory Function Tests; 5. Swimming [*physiology]; 6. Time Factors;
MESH terms:
Inhaled corticosteroids for subacute cough in children
1. Acute Disease; 2. Administration, Inhalation; 3. Adrenal Cortex Hormones [*administration & dosage]; 4. Cough [*drug therapy]; 5. Treatment Outcome;
MESH terms:
Lung protective ventilation strategy for the acute respiratory distress syndrome
1. Acute Lung Injury [*mortality, therapy]; 2. Randomized Controlled Trials as Topic; 3. Respiration, Artificial [*methods, mortality]; 4. Respiratory Distress Syndrome [*mortality, therapy]; 5. Tidal Volume;
MESH terms:
Partial liquid ventilation for the prevention of mortality and morbidity in paediatric acute lung injury and acute respiratory distress syndrome
1. Acute Lung Injury [complications, mortality, *therapy]; 2. Liquid Ventilation [*methods, mortality]; 3. Randomized Controlled Trials as Topic; 4. Respiratory Distress Syndrome [complications, mortality, *therapy]; 5. Respiratory Distress Syndrome, Newborn [complications, mortality, *therapy];
MESH terms:
Ciclesonide versus other inhaled corticosteroids for chronic asthma in children
1. Adrenal Cortex Hormones [*administration & dosage, adverse effects]; 2. Androstadienes [administration & dosage, adverse effects]; 3. Anti‐Asthmatic Agents [*administration & dosage, adverse effects]; 4. Asthma [*drug therapy]; 5. Budesonide [administration & dosage, adverse effects]; 6. Fluticasone; 7. Pregnenediones [*administration & dosage, adverse effects]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults
1. Administration, Inhalation; 2. Adrenal Cortex Hormones [*administration & dosage]; 3. Anti‐Asthmatic Agents [*administration & dosage]; 4. Asthma [*drug therapy]; 5. Disease Progression; 6. Drug Administration Schedule; 7. Randomized Controlled Trials as Topic;
MESH terms:
Psychosocial interventions for reducing antipsychotic medication in care home residents
1. Activities of Daily Living; 2. *Antipsychotic Agents [adverse effects]; 3. Psychosocial Intervention; 4. Quality of Life; 5. Restraint, Physical;
MESH terms:
Interventions for preventing and reducing the use of physical restraints for older people in all long‐term care settings
1. *Dementia [prevention & control]; 2. *Long-Term Care; 3. Nursing Homes; 4. Quality of Life; 5. Restraint, Physical;
MESH terms:
Cognitive behavioural therapy plus standard care versus standard care for persistent aggressive behaviour or agitation in people with schizophrenia
1. Aggression; 2. Anxiety; 3. *Cognitive Behavioral Therapy [methods]; 4. *Psychotic Disorders; 5. *Schizophrenia [complications, therapy];
MESH terms:
Cognitive rehabilitation for people with mild to moderate dementia
1. Activities of Daily Living; 2. *Alzheimer Disease; 3. Anxiety; 4. Cognitive Training; 5. *Dementia;
MESH terms:
Personally tailored activities for improving psychosocial outcomes for people with dementia in long‐term care
1. Affect; 2. Anxiety; 3. *Dementia [psychology]; 4. *Long-Term Care; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Cognitive stimulation to improve cognitive functioning in people with dementia
1. Cognition [*physiology]; 2. Dementia [*therapy]; 3. Memory [physiology]; 4. Orientation [*physiology]; 5. Psychotherapy [*methods]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Non‐pharmacological interventions for sleep disturbances in people with dementia
1. Caregivers [psychology]; 2. *Dementia [complications]; 3. Quality of Life; 4. Randomized Controlled Trials as Topic; 5. *Sleep Wake Disorders [epidemiology, therapy];
MESH terms:
Pharmacological interventions for the treatment of disordered and problem gambling
1. Anticonvulsants [therapeutic use]; 2. Antidepressive Agents [therapeutic use]; 3. *Antipsychotic Agents [therapeutic use]; 4. *Gambling [drug therapy]; 5. Headache; 6. Naltrexone; 7. Narcotic Antagonists [therapeutic use]; 8. Nausea [drug therapy]; 9. Olanzapine;
MESH terms:
Interventions for preventing and reducing the use of physical restraints of older people in general hospital settings
1. Emergency Service, Hospital; 2. Hospitalization; 3. *Hospitals, General; 4. Randomized Controlled Trials as Topic; 5. *Restraint, Physical;
MESH terms:
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia
1. Aspirin [therapeutic use]; 2. *Cerebral Small Vessel Diseases [complications, diagnostic imaging, drug therapy]; 3. *Cognitive Dysfunction [drug therapy, prevention & control]; 4. *Dementia [prevention & control]; 5. Neuroimaging; 6. Platelet Aggregation Inhibitors [therapeutic use]; 7. *Stroke [diagnostic imaging, drug therapy, prevention & control];
MESH terms:
Algorithm‐based pain management for people with dementia in nursing homes
1. Algorithms; 2. *Dementia [complications, psychology]; 3. Nursing Homes; 4. *Pain Management [methods]; 5. Quality of Life;
MESH terms:
Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD)
1. Hydrocortisone [therapeutic use]; 2. Paroxetine; 3. Psychotherapy [methods]; 4. Quality of Life; 5. *Stress Disorders, Post-Traumatic [psychology];
MESH terms:
Non‐pharmacological interventions for preventing delirium in hospitalised non‐ICU patients
1. *Delirium [prevention & control]; 2. Hospitalization; 3. Incidence; 4. Inpatients; 5. *Medication Review;
MESH terms:
Multi‐domain interventions for the prevention of dementia and cognitive decline
1. Activities of Daily Living; 2. Cognition; 3. *Cognitive Dysfunction; 4. *Dementia [prevention & control]; 5. Quality of Life;
MESH terms:
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder
1. *Bipolar Disorder [drug therapy]; 2. Depression [drug therapy]; 3. *Ketamine [therapeutic use]; 4. Quality of Life; 5. Receptors, Glutamate;
MESH terms:
Lamotrigine in the maintenance treatment of bipolar disorder
1. Anticonvulsants [therapeutic use]; 2. *Bipolar Disorder [drug therapy]; 3. Lamotrigine [adverse effects]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic;
MESH terms:
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder
1. Antidepressive Agents [therapeutic use]; 2. Depression; 3. *Depressive Disorder, Major [drug therapy]; 4. *Ketamine [therapeutic use]; 5. Receptors, Glutamate [therapeutic use];
MESH terms:
Enteral tube feeding for people with severe dementia
1. Caregivers; 2. Dementia [*complications]; 3. *Enteral Nutrition; 4. Gastrostomy; 5. Intubation, Gastrointestinal [adverse effects]; 6. Malnutrition [*prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Treatment Outcome;
MESH terms:
Magnetic seizure therapy for treatment‐resistant depression
1. Antidepressive Agents [therapeutic use]; 2. Bias; 3. Cognition; 4. Depression [diagnosis, drug therapy, *therapy]; 5. Drug Resistance; 6. Electroconvulsive Therapy; 7. Magnetic Field Therapy [adverse effects, *methods]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Schizophrenia [therapy]; 11. Symptom Assessment;
MESH terms:
Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia
1. Alzheimer Disease [*prevention & control]; 2. Antihypertensive Agents [*therapeutic use]; 3. Cognition Disorders [*prevention & control]; 4. Dementia, Vascular [*prevention & control]; 5. Hypertension [complications, *drug therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Approaches for discontinuation versus continuation of long‐term antidepressant use for depressive and anxiety disorders in adults
1. Antidepressive Agents [*therapeutic use]; 2. Anxiety Disorders [*drug therapy]; 3. Cognitive Behavioral Therapy; 4. Depression [*drug therapy]; 5. Drug Tapering; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Recurrence; 9. Time Factors; 10. *Withholding Treatment;
MESH terms:
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis
1. Activities of Daily Living; 2. Bias; 3. Cholinesterase Inhibitors [*administration & dosage, adverse effects]; 4. Cognition [drug effects]; 5. Dementia, Vascular [*drug therapy]; 6. Donepezil [*administration & dosage, adverse effects]; 7. Galantamine [*administration & dosage, adverse effects]; 8. *Network Meta-Analysis; 9. Nootropic Agents [administration & dosage, adverse effects]; 10. Physical Functional Performance; 11. Placebos [therapeutic use]; 12. Randomized Controlled Trials as Topic; 13. Rivastigmine [*administration & dosage, adverse effects];
MESH terms:
Antidepressant treatment for postnatal depression
1. Antidepressive Agents [adverse effects, *therapeutic use]; 2. Bias; 3. Depression, Postpartum [*drug therapy]; 4. Patient Dropouts [statistics & numerical data]; 5. Placebos [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Selective Serotonin Reuptake Inhibitors [adverse effects, *therapeutic use]; 8. Treatment Outcome;
MESH terms:
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia
1. Activities of Daily Living; 2. *Alzheimer Disease [drug therapy]; 3. Cholinesterase Inhibitors [adverse effects]; 4. *Dementia [chemically induced, drug therapy]; 5. Donepezil [adverse effects]; 6. Memantine [adverse effects]; 7. *Parkinson Disease [drug therapy]; 8. Quality of Life; 9. Rivastigmine [adverse effects];
MESH terms:
Pharmacological interventions for self‐harm in adults
1. Antidepressive Agents [therapeutic use]; 2. *Antipsychotic Agents [therapeutic use]; 3. *Biological Products; 4. Randomized Controlled Trials as Topic; 5. *Self-Injurious Behavior [therapy]; 6. Systematic Reviews as Topic;
MESH terms:
Remotely delivered information, training and support for informal caregivers of people with dementia
1. Affect; 2. Bias; 3. Caregiver Burden [*prevention & control]; 4. Caregivers [*education, psychology]; 5. Dementia [*nursing]; 6. Family; 7. Health Services Accessibility [statistics & numerical data]; 8. Health Services Needs and Demand [statistics & numerical data]; 9. Institutionalization [statistics & numerical data]; 10. Nursing Homes [statistics & numerical data]; 11. Quality of Life; 12. Randomized Controlled Trials as Topic;
MESH terms:
Personally tailored activities for improving psychosocial outcomes for people with dementia in community settings
1. Caregivers [education, psychology]; 2. Cost of Illness; 3. Dementia [psychology, *rehabilitation]; 4. Depression [rehabilitation]; 5. *Independent Living; 6. Mental Status and Dementia Tests [statistics & numerical data]; 7. *Patient Preference; 8. Problem Behavior [psychology]; 9. Psychological Distress; 10. *Quality of Life; 11. Randomized Controlled Trials as Topic; 12. *Social Participation; 13. Spouses [education, psychology]; 14. Treatment Outcome;
MESH terms:
Behavioural activation therapy for depression in adults with non‐communicable diseases
1. Behavior Therapy [*methods]; 2. Bias; 3. Breast Neoplasms [*psychology]; 4. Conflict of Interest; 5. Depression [*therapy]; 6. Noncommunicable Diseases [*psychology]; 7. Patient Acceptance of Health Care; 8. Problem Solving; 9. Randomized Controlled Trials as Topic; 10. Stroke [*psychology]; 11. Treatment Outcome;
MESH terms:
Avatar Therapy for people with schizophrenia or related disorders
1. Anxiety [etiology]; 2. Bias; 3. Confidence Intervals; 4. Hallucinations [*therapy]; 5. Intention to Treat Analysis; 6. Mental Health; 7. Odds Ratio; 8. Patient Dropouts [psychology, statistics & numerical data]; 9. Psychotic Disorders [therapy]; 10. Quality of Life; 11. Randomized Controlled Trials as Topic; 12. Recurrence; 13. Schizophrenia [*therapy]; 14. Schizophrenic Psychology; 15. Therapies, Investigational [adverse effects, *methods]; 16. Therapy, Computer-Assisted [methods]; 17. Virtual Reality Exposure Therapy [*methods];
MESH terms:
Aspirin and other non‐steroidal anti‐inflammatory drugs for the prevention of dementia
1. Activities of Daily Living; 2. Alzheimer Disease [epidemiology, prevention & control]; 3. Anti-Inflammatory Agents, Non-Steroidal [administration & dosage, adverse effects, *therapeutic use]; 4. Aspirin [administration & dosage, adverse effects, *therapeutic use]; 5. Celecoxib [administration & dosage, adverse effects, therapeutic use]; 6. Cyclooxygenase 2 Inhibitors [administration & dosage, adverse effects, therapeutic use]; 7. Dementia [epidemiology, mortality, *prevention & control]; 8. Hemorrhage [chemically induced, epidemiology]; 9. Incidence; 10. Lactones [therapeutic use]; 11. Myocardial Infarction [epidemiology]; 12. Naproxen [therapeutic use]; 13. Randomized Controlled Trials as Topic; 14. Stroke [epidemiology]; 15. Sulfones [therapeutic use];
MESH terms:
Simulated presence therapy for dementia
1. Dementia [psychology, *therapy]; 2. Depression [*therapy]; 3. *Family; 4. Psychomotor Agitation [*therapy]; 5. Randomized Controlled Trials as Topic; 6. *Tape Recording; 7. *Videotape Recording;
MESH terms:
Computerised cognitive training for 12 or more weeks for maintaining cognitive function in cognitively healthy people in late life
1. *Cognition; 2. Activities of Daily Living; 3. Cognitive Dysfunction [*prevention & control]; 4. Computer‐Assisted Instruction; 5. Healthy Aging; 6. Memory, Episodic; 7. Quality of Life; 8. Randomized Controlled Trials as Topic;
MESH terms:
Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s disease
1. Activities of Daily Living; 2. Cognitive Dysfunction [rehabilitation, *therapy]; 3. Dementia [rehabilitation, *therapy]; 4. Parkinson Disease [*psychology]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Task Performance and Analysis;
MESH terms:
Enhanced rehabilitation and care models for adults with dementia following hip fracture surgery
1. *Patient Care Team; 2. Activities of Daily Living; 3. Delirium [prevention & control]; 4. Dementia [*complications]; 5. Hip Fractures [*rehabilitation, surgery]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Psychosocial interventions for people with both severe mental illness and substance misuse
1. *Cognitive Behavioral Therapy; 2. Hospitalization [statistics & numerical data]; 3. Mental Disorders [*therapy]; 4. Psychotherapy; 5. Randomized Controlled Trials as Topic; 6. Recurrence; 7. Substance‐Related Disorders [*therapy];
MESH terms:
Couple and family therapies for post‐traumatic stress disorder (PTSD)
1. *Cognitive Behavioral Therapy; 2. *Family Therapy; 3. Interpersonal Relations; 4. Marital Therapy; 5. Patient Dropouts [statistics & numerical data]; 6. Randomized Controlled Trials as Topic; 7. Stress Disorders, Post‐Traumatic [*therapy]; 8. Treatment Outcome; 9. Waiting Lists;
MESH terms:
Present‐centered therapy (PCT) for post‐traumatic stress disorder (PTSD) in adults
1. Cognitive Behavioral Therapy [*methods]; 2. Patient Dropouts [statistics & numerical data]; 3. Quality of Life; 4. Randomized Controlled Trials as Topic; 5. Stress Disorders, Post‐Traumatic [psychology, *therapy]; 6. Treatment Outcome; 7. Waiting Lists;
MESH terms:
Cerebrolysin for vascular dementia
1. Amino Acids [adverse effects, *therapeutic use]; 2. Cognition [drug effects]; 3. Cost of Illness; 4. Dementia, Vascular [*drug therapy, psychology]; 5. Nootropic Agents [*therapeutic use]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Pharmacological interventions for the treatment of delirium in critically ill adults
1. *Critical Illness; 2. Antipsychotic Agents [*therapeutic use]; 3. Delirium [*drug therapy]; 4. Network Meta‐Analysis; 5. Randomized Controlled Trials as Topic;
MESH terms:
Multiple session early psychological interventions for the prevention of post‐traumatic stress disorder
1. *Cognitive Behavioral Therapy [methods]; 2. Desensitization, Psychologic; 3. Psychotherapy [methods]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Stress Disorders, Post‐Traumatic [*prevention & control]; 7. Time Factors; 8. Waiting Lists;
MESH terms:
Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses
1. Antipsychotic Agents [therapeutic use]; 2. Benzodiazepines [*therapeutic use]; 3. Catatonia [*drug therapy]; 4. Electroconvulsive Therapy; 5. Mental Disorders [complications]; 6. Randomized Controlled Trials as Topic; 7. Schizophrenia [drug therapy]; 8. Schizophrenia, Catatonic [*drug therapy];
MESH terms:
Antidepressants plus benzodiazepines for adults with major depression
1. *Antidepressive Agents [therapeutic use]; 2. Anxiety [drug therapy]; 3. *Benzodiazepines [therapeutic use]; 4. *Depressive Disorder, Major [drug therapy]; 5. Drug Therapy, Combination;
MESH terms:
Psychological therapies for preventing seasonal affective disorder
1. Antidepressive Agents [therapeutic use]; 2. Cognitive Behavioral Therapy; 3. Depressive Disorder, Major [*therapy]; 4. Melatonin [therapeutic use]; 5. Phototherapy; 6. Randomized Controlled Trials as Topic; 7. Seasonal Affective Disorder [*prevention & control, therapy];
MESH terms:
Interventions for preventing delirium in older people in institutional long‐term care
1. *Long‐Term Care; 2. Activities of Daily Living; 3. Delirium [chemically induced, epidemiology, *prevention & control]; 4. Frail Elderly; 5. Incidence; 6. Institutionalization; 7. Medication Reconciliation; 8. Quality of Life; 9. Randomized Controlled Trials as Topic;
MESH terms:
Benzodiazepines versus placebo for panic disorder in adults
1. Agoraphobia [complications, drug therapy]; 2. Benzodiazepines [*therapeutic use]; 3. Buspirone [therapeutic use]; 4. Imipramine [therapeutic use]; 5. Numbers Needed To Treat; 6. Panic Disorder [complications, *drug therapy]; 7. Paroxetine [therapeutic use]; 8. Patient Dropouts [statistics & numerical data]; 9. Placebos [therapeutic use]; 10. Propranolol [therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Remission Induction;
MESH terms:
Cognitive training for people with mild to moderate dementia
1. *Cognition; 2. Activities of Daily Living; 3. Cognitive Dysfunction [rehabilitation, *therapy]; 4. Dementia [complications, rehabilitation, *therapy]; 5. Randomized Controlled Trials as Topic; 6. Task Performance and Analysis; 7. Therapy, Computer‐Assisted [methods];
MESH terms:
Memantine for dementia
1. Activities of Daily Living; 2. Akathisia, Drug‐Induced [etiology]; 3. Alzheimer Disease [drug therapy]; 4. Cognition Disorders [drug therapy]; 5. Dementia [*drug therapy]; 6. Dementia, Vascular [drug therapy]; 7. Excitatory Amino Acid Antagonists [adverse effects, *therapeutic use]; 8. Memantine [adverse effects, *therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Withholding Treatment;
MESH terms:
Electroconvulsive therapy for treatment‐resistant schizophrenia
1. Antipsychotic Agents [therapeutic use]; 2. Brief Psychiatric Rating Scale; 3. Electroconvulsive Therapy [*adverse effects, methods]; 4. Flupenthixol [therapeutic use]; 5. Memory Disorders [*etiology]; 6. Patient Readmission [statistics & numerical data]; 7. Piperazines [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Schizophrenia [*therapy]; 10. Standard of Care; 11. Thiazoles [therapeutic use]; 12. Treatment Outcome;
MESH terms:
Second‐generation antidepressants for preventing seasonal affective disorder in adults
1. Antidepressive Agents, Second‐Generation [adverse effects, *therapeutic use]; 2. Bupropion [adverse effects, *therapeutic use]; 3. Diarrhea [chemically induced]; 4. Headache [chemically induced]; 5. Incidence; 6. Nausea [chemically induced]; 7. Numbers Needed To Treat; 8. Randomized Controlled Trials as Topic; 9. Recurrence; 10. Seasonal Affective Disorder [*drug therapy, epidemiology]; 11. Sleep Initiation and Maintenance Disorders [chemically induced];
MESH terms:
Computerised cognitive training for preventing dementia in people with mild cognitive impairment
1. Cognition; 2. Cognitive Dysfunction [*complications]; 3. Computer‐Assisted Instruction [*methods]; 4. Dementia [*prevention & control]; 5. Disease Progression; 6. Executive Function; 7. Memory, Episodic; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Time Factors;
MESH terms:
Computerised cognitive training for maintaining cognitive function in cognitively healthy people in midlife
1. *Cognition; 2. *Computer‐Assisted Instruction; 3. *Healthy Aging; 4. Cognitive Dysfunction [*prevention & control]; 5. Dementia [prevention & control]; 6. Memory, Episodic; 7. Time Factors;
MESH terms:
Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia
1. Ambulatory Care; 2. Cognitive Behavioral Therapy [*methods]; 3. Combined Modality Therapy [methods]; 4. Patient Readmission [statistics & numerical data]; 5. Patient Satisfaction; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Recurrence; 9. Schizophrenia [mortality, *therapy]; 10. Schizophrenic Psychology; 11. Social Behavior;
MESH terms:
Interventions for preventing intensive care unit delirium in adults
1. *Cognitive Behavioral Therapy; 2. *Intensive Care Units; 3. *Physical Therapy Modalities; 4. Antipsychotic Agents [*therapeutic use]; 5. Cognition Disorders [diagnosis]; 6. Delirium [mortality, *prevention & control]; 7. Haloperidol [*therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia
1. Cognitive Behavioral Therapy [*methods]; 2. Combined Modality Therapy [methods]; 3. Patient Readmission [statistics & numerical data]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Recurrence; 7. Schizophrenia [mortality, *therapy]; 8. Schizophrenic Psychology; 9. Social Behavior;
MESH terms:
Valproate preparations for agitation in dementia
1. Aggression [drug effects]; 2. Antimanic Agents [adverse effects, *therapeutic use]; 3. Cognition [drug effects]; 4. Dementia [*complications]; 5. Psychomotor Agitation [*drug therapy, etiology]; 6. Randomized Controlled Trials as Topic; 7. Treatment Outcome; 8. Valproic Acid [adverse effects, *therapeutic use];
MESH terms:
Antidepressants for treating depression in dementia
1. Activities of Daily Living; 2. Antidepressive Agents [*therapeutic use]; 3. Cognition; 4. Dementia [*psychology]; 5. Depression [*drug therapy]; 6. Patient Dropouts [statistics & numerical data]; 7. Randomized Controlled Trials as Topic; 8. Remission Induction; 9. Time Factors; 10. Treatment Outcome;
MESH terms:
Environmental and behavioural modifications for improving food and fluid intake in people with dementia
1. Alzheimer Disease [complications, psychology]; 2. Dementia [*complications, psychology]; 3. Dietary Proteins [administration & dosage]; 4. Energy Intake; 5. *Meals; 6. Nutrition Disorders [*diet therapy]; 7. Nutritional Status; 8. *Patient Education as Topic; 9. Randomized Controlled Trials as Topic; 10. Time Factors;
MESH terms:
Cholinesterase inhibitors for the treatment of delirium in non‐ICU settings
1. Cholinesterase Inhibitors [adverse effects, *therapeutic use]; 2. Delirium [*drug therapy, mortality]; 3. Length of Stay; 4. Nausea [chemically induced]; 5. Rivastigmine [adverse effects, *therapeutic use];
MESH terms:
Donepezil for dementia due to Alzheimer's disease
1. Alzheimer Disease [*drug therapy]; 2. Cholinesterase Inhibitors [*therapeutic use]; 3. Cognition [drug effects]; 4. Cognition Disorders [drug therapy]; 5. Donepezil; 6. Indans [*therapeutic use]; 7. Nootropic Agents [*therapeutic use]; 8. Piperidines [*therapeutic use]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Couple therapy for depression
1. *Interpersonal Relations; 2. *Marital Therapy; 3. Antidepressive Agents [therapeutic use]; 4. Depression [epidemiology, *therapy]; 5. Patient Dropouts [statistics & numerical data]; 6. Randomized Controlled Trials as Topic; 7. Sex Factors;
MESH terms:
Processed electroencephalogram and evoked potential techniques for amelioration of postoperative delirium and cognitive dysfunction following non‐cardiac and non‐neurosurgical procedures in adults
1. *Electroencephalography; 2. *Evoked Potentials, Auditory; 3. Anesthesia, General [methods]; 4. Anesthetics [*administration & dosage]; 5. Cause of Death; 6. Cognitive Dysfunction [*prevention & control]; 7. Consciousness; 8. Delirium [*prevention & control]; 9. Entropy; 10. Postoperative Complications [*prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Surgical Procedures, Operative [*adverse effects];
MESH terms:
Antidepressants for preventing postnatal depression
1. Antidepressive Agents [*therapeutic use]; 2. Depression, Postpartum [*prevention & control]; 3. Nortriptyline [*therapeutic use]; 4. Placebos [therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Sertraline [*therapeutic use];
MESH terms:
Gamma‐aminobutyric acid agonists for antipsychotic‐induced tardive dyskinesia
1. Antipsychotic Agents [adverse effects]; 2. Baclofen [therapeutic use]; 3. Dyskinesia, Drug‐Induced [*drug therapy, etiology]; 4. GABA Agonists [adverse effects, *therapeutic use]; 5. Isoxazoles [therapeutic use]; 6. Placebos [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Valproic Acid [therapeutic use]; 9. gamma‐Aminobutyric Acid [analogs & derivatives, therapeutic use];
MESH terms:
Antidepressants versus placebo for panic disorder in adults
1. Agoraphobia [*drug therapy]; 2. Antidepressive Agents [adverse effects, *therapeutic use]; 3. Numbers Needed To Treat; 4. Panic Disorder [*drug therapy]; 5. Patient Dropouts [statistics & numerical data]; 6. Placebos [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Treatment Failure;
MESH terms:
Withdrawal versus continuation of long‐term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Dementia [*psychology]; 3. Mental Disorders [*drug therapy]; 4. Psychomotor Agitation [*drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Recurrence;
MESH terms:
Calcium channel blockers for antipsychotic‐induced tardive dyskinesia
1. Antipsychotic Agents [*adverse effects]; 2. Calcium Channel Blockers [*therapeutic use]; 3. Diltiazem [*therapeutic use]; 4. Dyskinesia, Drug‐Induced [*drug therapy]; 5. Flunarizine [*therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Schizophrenia [drug therapy];
MESH terms:
Cholinergic medication for antipsychotic‐induced tardive dyskinesia
1. Antipsychotic Agents [*adverse effects]; 2. Cholinergic Agents [adverse effects, *therapeutic use]; 3. Dyskinesia, Drug‐Induced [*drug therapy, etiology]; 4. Patient Dropouts; 5. Randomized Controlled Trials as Topic;
MESH terms:
Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia
1. Adrenergic Uptake Inhibitors [therapeutic use]; 2. Anti‐Anxiety Agents [therapeutic use]; 3. Antipsychotic Agents [adverse effects]; 4. Dihydroergotoxine [therapeutic use]; 5. Dyskinesia, Drug‐Induced [etiology, *therapy]; 6. Ginkgo biloba; 7. Hypnosis; 8. Plant Extracts; 9. Randomized Controlled Trials as Topic; 10. Relaxation Therapy; 11. Tetrabenazine [analogs & derivatives, therapeutic use]; 12. Valine [analogs & derivatives, therapeutic use];
MESH terms:
Selective noradrenaline reuptake inhibitors for schizophrenia
1. Adrenergic Uptake Inhibitors [*therapeutic use]; 2. Atomoxetine Hydrochloride [therapeutic use]; 3. Citalopram [therapeutic use]; 4. Cognition [drug effects]; 5. Morpholines [therapeutic use]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Reboxetine; 9. Schizophrenia [*drug therapy]; 10. Serotonin and Noradrenaline Reuptake Inhibitors [*therapeutic use]; 11. Viloxazine [therapeutic use];
MESH terms:
Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse
1. Antipsychotic Agents [*therapeutic use]; 2. Benzodiazepines [therapeutic use]; 3. Clozapine [therapeutic use]; 4. Diagnosis, Dual (Psychiatry); 5. Mental Disorders [*drug therapy]; 6. Olanzapine; 7. Patient Dropouts [statistics & numerical data]; 8. Perphenazine [therapeutic use]; 9. Piperazines [therapeutic use]; 10. Quetiapine Fumarate [therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Risperidone [*therapeutic use]; 13. Schizophrenia [drug therapy]; 14. Substance‐Related Disorders [*drug therapy, psychology]; 15. Thiazoles [therapeutic use];
MESH terms:
Benzodiazepines for antipsychotic‐induced tardive dyskinesia
1. Anti‐Anxiety Agents [*therapeutic use]; 2. Antipsychotic Agents [adverse effects]; 3. Benzodiazepines [*therapeutic use]; 4. Clonazepam [therapeutic use]; 5. Dyskinesia, Drug‐Induced [*drug therapy, etiology]; 6. GABA Modulators [*therapeutic use]; 7. Phenobarbital [therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia
1. Adrenergic Uptake Inhibitors [therapeutic use]; 2. Anti‐Dyskinesia Agents [*therapeutic use]; 3. Antipsychotic Agents [*adverse effects]; 4. Celiprolol [therapeutic use]; 5. Disease Progression; 6. Dopamine Antagonists [therapeutic use]; 7. Dyskinesia, Drug‐Induced [*drug therapy]; 8. Haloperidol [therapeutic use]; 9. Methyldopa [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Reserpine [therapeutic use]; 12. Tetrabenazine [therapeutic use]; 13. Tiapamil Hydrochloride [therapeutic use];
MESH terms:
Anticholinergic medication for antipsychotic‐induced tardive dyskinesia
1. Antipsychotic Agents [*adverse effects]; 2. Biperiden [adverse effects, therapeutic use]; 3. Cholinergic Antagonists [adverse effects, *therapeutic use]; 4. Dyskinesia, Drug‐Induced [*drug therapy, etiology]; 5. Isocarboxazid [adverse effects, therapeutic use]; 6. Procyclidine [adverse effects, therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Schizophrenia [drug therapy]; 9. Withholding Treatment;
MESH terms:
Aripiprazole (intramuscular) for psychosis‐induced aggression or agitation (rapid tranquillisation)
1. Aggression [*drug effects, psychology]; 2. Antipsychotic Agents [*administration & dosage, adverse effects]; 3. Aripiprazole [*administration & dosage, adverse effects]; 4. Benzodiazepines [administration & dosage]; 5. Haloperidol [administration & dosage]; 6. Injections, Intramuscular; 7. Olanzapine; 8. Psychomotor Agitation [*drug therapy, psychology]; 9. Randomized Controlled Trials as Topic; 10. Tranquilizing Agents [administration & dosage];
MESH terms:
Benzodiazepines for psychosis‐induced aggression or agitation
1. Acute Disease; 2. Aggression [drug effects]; 3. Anti-Dyskinesia Agents [therapeutic use]; 4. Antipsychotic Agents [*therapeutic use]; 5. Benzodiazepines [*therapeutic use]; 6. Drug Therapy, Combination [methods]; 7. Emergency Treatment [methods]; 8. Haloperidol [therapeutic use]; 9. Lorazepam [therapeutic use]; 10. Olanzapine; 11. Psychomotor Agitation [drug therapy]; 12. Psychotic Disorders [*drug therapy]; 13. Randomized Controlled Trials as Topic;
MESH terms:
Zuclopenthixol dihydrochloride for schizophrenia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Clopenthixol [adverse effects, *therapeutic use]; 3. Movement Disorders [etiology]; 4. Randomized Controlled Trials as Topic; 5. Schizophrenia [*drug therapy];
MESH terms:
Chlorpromazine versus penfluridol for schizophrenia
1. Akathisia, Drug‐Induced [epidemiology]; 2. Antipsychotic Agents [adverse effects, *therapeutic use]; 3. Chlorpromazine [adverse effects, *therapeutic use]; 4. Length of Stay; 5. Penfluridol [adverse effects, *therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Schizophrenia [*drug therapy];
MESH terms:
Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation)
1. Aggression [*drug effects, psychology]; 2. Antipsychotic Agents [administration & dosage, adverse effects]; 3. Dystonia [chemically induced]; 4. Haloperidol [*administration & dosage, adverse effects]; 5. Hypnotics and Sedatives [administration & dosage, adverse effects]; 6. Placebos [therapeutic use]; 7. Psychomotor Agitation [*drug therapy]; 8. Psychotic Disorders [*drug therapy, psychology]; 9. Randomized Controlled Trials as Topic; 10. Sleep; 11. Tranquilizing Agents [adverse effects, *therapeutic use];
MESH terms:
Vortioxetine for depression in adults
1. Antidepressive Agents [*therapeutic use]; 2. Depressive Disorder, Major [*drug therapy]; 3. Duloxetine Hydrochloride [therapeutic use]; 4. Patient Dropouts [statistics & numerical data]; 5. Piperazines [*therapeutic use]; 6. Placebos [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Remission Induction; 9. Serotonin and Noradrenaline Reuptake Inhibitors [therapeutic use]; 10. Sulfides [*therapeutic use]; 11. Venlafaxine Hydrochloride [therapeutic use]; 12. Vortioxetine;
MESH terms:
Antipsychotic combinations for schizophrenia
1. Antipsychotic Agents [*therapeutic use]; 2. Clozapine [therapeutic use]; 3. Drug Therapy, Combination; 4. Patient Dropouts [statistics & numerical data]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Schizophrenia [*drug therapy]; 9. Treatment Outcome;
MESH terms:
Communication skills training for mental health professionals working with people with severe mental illness
1. *Communication; 2. *Patient Satisfaction; 3. Mental Health [*education]; 4. Patient Compliance; 5. Physician‐Patient Relations; 6. Pilot Projects; 7. Psychiatry [*education]; 8. Psychotic Disorders [*therapy]; 9. Randomized Controlled Trials as Topic; 10. Schizophrenia [*therapy];
MESH terms:
Assistive technology for memory support in dementia
1. *Dementia; 2. *Electronics, Medical; 3. *Memory; 4. *Self‐Help Devices; 5. Activities of Daily Living;
MESH terms:
Chlorpromazine versus clotiapine for schizophrenia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Chlorpromazine [adverse effects, *therapeutic use]; 3. Dibenzothiazepines [adverse effects, *therapeutic use]; 4. Dyskinesia, Drug‐Induced [epidemiology]; 5. Intention to Treat Analysis; 6. Patient Dropouts [statistics & numerical data]; 7. Randomized Controlled Trials as Topic; 8. Risk; 9. Schizophrenia [*drug therapy];
MESH terms:
Chlorpromazine versus metiapine for schizophrenia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Chlorpromazine [adverse effects, *therapeutic use]; 3. Dibenzothiazepines [adverse effects, *therapeutic use]; 4. Parkinson Disease, Secondary [chemically induced]; 5. Randomized Controlled Trials as Topic; 6. Schizophrenia [*drug therapy]; 7. Treatment Outcome;
MESH terms:
Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia
1. Amisulpride; 2. Antipsychotic Agents [adverse effects, *therapeutic use]; 3. Aripiprazole [adverse effects, therapeutic use]; 4. Clozapine [adverse effects, *therapeutic use]; 5. Dibenzothiazepines [therapeutic use]; 6. Drug Resistance; 7. Drug Therapy, Combination; 8. Haloperidol [adverse effects, therapeutic use]; 9. Piperazines [therapeutic use]; 10. Quetiapine Fumarate; 11. Randomized Controlled Trials as Topic; 12. Risperidone [therapeutic use]; 13. Schizophrenia [*drug therapy]; 14. Sulpiride [adverse effects, analogs & derivatives, therapeutic use]; 15. Thiazoles [therapeutic use]; 16. Weight Gain;
MESH terms:
Compulsory community and involuntary outpatient treatment for people with severe mental disorders
1. Ambulatory Care [standards, statistics & numerical data]; 2. Commitment of Mentally Ill [*legislation & jurisprudence]; 3. Community Mental Health Services [*legislation & jurisprudence]; 4. Crime Victims; 5. Length of Stay [statistics & numerical data]; 6. Medication Adherence [statistics & numerical data]; 7. Mental Disorders [*therapy]; 8. Patient Readmission [legislation & jurisprudence, statistics & numerical data]; 9. Patient Satisfaction; 10. Quality of Life; 11. Randomized Controlled Trials as Topic; 12. Social Skills; 13. Treatment Outcome;
MESH terms:
Risperidone versus placebo for schizophrenia
1. Administration, Oral; 2. Antipsychotic Agents [*administration & dosage, adverse effects]; 3. Placebos [therapeutic use]; 4. Publication Bias; 5. Randomized Controlled Trials as Topic; 6. Risperidone [*administration & dosage, adverse effects]; 7. Schizophrenia [*drug therapy];
MESH terms:
Implementation of treatment guidelines for specialist mental health care
1. *Guideline Adherence; 2. *Outcome and Process Assessment, Health Care; 3. *Practice Guidelines as Topic; 4. *Specialization; 5. Antipsychotic Agents [*therapeutic use]; 6. Mental Health; 7. Randomized Controlled Trials as Topic; 8. Schizophrenia [*drug therapy];